Logo image of CYXT

CYXTERA TECHNOLOGIES INC (CYXT) Stock Fundamental Analysis

NASDAQ:CYXT - Nasdaq - US23284C1027 - Common Stock - Currency: USD

0.065  +0.02 (+55.5%)

After market: 0.0595 -0.01 (-8.46%)

Fundamental Rating

1

Overall CYXT gets a fundamental rating of 1 out of 10. We evaluated CYXT against 82 industry peers in the IT Services industry. CYXT has a bad profitability rating. Also its financial health evaluation is rather negative. CYXT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CYXT has reported negative net income.
In the past year CYXT had a positive cash flow from operations.
CYXT had negative earnings in each of the past 5 years.
Of the past 5 years CYXT 4 years had a positive operating cash flow.
CYXT Yearly Net Income VS EBIT VS OCF VS FCFCYXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 -200M -400M

1.2 Ratios

The profitability ratios for CYXT are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYXT Yearly ROA, ROE, ROICCYXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 -20 -40 -60 -80

1.3 Margins

CYXT has a better Gross Margin (46.37%) than 71.43% of its industry peers.
In the last couple of years the Gross Margin of CYXT has grown nicely.
The Profit Margin and Operating Margin are not available for CYXT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.68%
GM growth 5YN/A
CYXT Yearly Profit, Operating, Gross MarginsCYXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 20 -20 40 -40 -60

More info and screens

0

2. Health

2.1 Basic Checks

CYXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CYXT has more shares outstanding
Compared to 1 year ago, CYXT has a worse debt to assets ratio.
CYXT Yearly Shares OutstandingCYXT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 50M 100M 150M
CYXT Yearly Total Debt VS Total AssetsCYXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of -0.82, we must say that CYXT is in the distress zone and has some risk of bankruptcy.
CYXT's Altman-Z score of -0.82 is on the low side compared to the rest of the industry. CYXT is outperformed by 81.32% of its industry peers.
CYXT has a Debt/Equity ratio of 31.18. This is a high value indicating a heavy dependency on external financing.
CYXT's Debt to Equity ratio of 31.18 is on the low side compared to the rest of the industry. CYXT is outperformed by 81.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 31.18
Debt/FCF N/A
Altman-Z -0.82
ROIC/WACCN/A
WACC1.73%
CYXT Yearly LT Debt VS Equity VS FCFCYXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 0.43 indicates that CYXT may have some problems paying its short term obligations.
The Current ratio of CYXT (0.43) is worse than 90.11% of its industry peers.
CYXT has a Quick Ratio of 0.43. This is a bad value and indicates that CYXT is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.43, CYXT is doing worse than 89.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.43
Quick Ratio 0.43
CYXT Yearly Current Assets VS Current LiabilitesCYXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CYXT have decreased strongly by -19.83% in the last year.
The Revenue has been growing slightly by 6.60% in the past year.
Measured over the past years, CYXT shows a small growth in Revenue. The Revenue has been growing by 3.21% on average per year.
EPS 1Y (TTM)-19.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.04%
Revenue 1Y (TTM)6.6%
Revenue growth 3Y3.21%
Revenue growth 5YN/A
Sales Q2Q%7.84%

3.2 Future

The Earnings Per Share is expected to grow by 9.65% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.62% on average over the next years.
EPS Next Y8.38%
EPS Next 2Y9.18%
EPS Next 3Y9.65%
EPS Next 5YN/A
Revenue Next Year5%
Revenue Next 2Y4.78%
Revenue Next 3Y5.1%
Revenue Next 5Y4.62%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CYXT Yearly Revenue VS EstimatesCYXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
CYXT Yearly EPS VS EstimatesCYXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CYXT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CYXT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYXT Price Earnings VS Forward Price EarningsCYXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CYXT is valued a bit cheaper than the industry average as 73.63% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.15
CYXT Per share dataCYXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.18%
EPS Next 3Y9.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYXT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYXTERA TECHNOLOGIES INC

NASDAQ:CYXT (6/14/2023, 9:24:44 PM)

After market: 0.0595 -0.01 (-8.46%)

0.065

+0.02 (+55.5%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)05-04 2023-05-04/bmo
Earnings (Next)08-09 2023-08-09/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners1.64%
Ins Owner Change0%
Market Cap11.68M
Analysts74.55
Price Target1.34 (1961.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.6%
Min EPS beat(2)-25.49%
Max EPS beat(2)50.7%
EPS beat(4)1
Avg EPS beat(4)-12.29%
Min EPS beat(4)-42.11%
Max EPS beat(4)50.7%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.79%
Min Revenue beat(2)-0.95%
Max Revenue beat(2)-0.63%
Revenue beat(4)0
Avg Revenue beat(4)-1.57%
Min Revenue beat(4)-2.44%
Max Revenue beat(4)-0.63%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-53.95%
PT rev (3m)-73.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-44.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF 0.12
P/B 0.18
P/tB N/A
EV/EBITDA 10.15
EPS(TTM)-1.16
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)0.55
OCFY842.51%
SpS4.23
BVpS0.36
TBVpS-3.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.37%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.68%
GM growth 5YN/A
F-Score4
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 31.18
Debt/FCF N/A
Debt/EBITDA 10.41
Cap/Depr 55.21%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.43
Quick Ratio 0.43
Altman-Z -0.82
F-Score4
WACC1.73%
ROIC/WACCN/A
Cap/Depr(3y)40.78%
Cap/Depr(5y)40.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.04%
EPS Next Y8.38%
EPS Next 2Y9.18%
EPS Next 3Y9.65%
EPS Next 5YN/A
Revenue 1Y (TTM)6.6%
Revenue growth 3Y3.21%
Revenue growth 5YN/A
Sales Q2Q%7.84%
Revenue Next Year5%
Revenue Next 2Y4.78%
Revenue Next 3Y5.1%
Revenue Next 5Y4.62%
EBIT growth 1Y-6.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year667.96%
EBIT Next 3Y107.59%
EBIT Next 5Y61.88%
FCF growth 1Y33.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y277.52%
OCF growth 3YN/A
OCF growth 5YN/A